Ovarian Progression-Free Survival Acceptable If Trial Is Powered For Survival
Executive Summary
Progression-free survival is an acceptable basis for accelerated approval of ovarian cancer agents, so long as trials are powered for survival, panelists at FDA's April 26 Ovarian Cancer Endpoint Workshop in Bethesda, Md. said
You may also be interested in...
Progression-Free Survival Represents Clinical Benefit, But How Much? – ODAC
While the Oncologic Drugs Advisory Committee generally endorses the idea that progression-free survival can support full approval of first-line therapies in metastatic breast cancer, the panel left FDA with the challenge of qualifying how PFS represents clinical benefit and determining the measure's meaningfulness for regulatory purposes
Progression-Free Survival Represents Clinical Benefit, But How Much? – ODAC
While the Oncologic Drugs Advisory Committee generally endorses the idea that progression-free survival can support full approval of first-line therapies in metastatic breast cancer, the panel left FDA with the challenge of qualifying how PFS represents clinical benefit and determining the measure's meaningfulness for regulatory purposes
FDA Cancer Endpoint Guidance Abandons Placebos, Moves Beyond Survival
FDA's final guidance on cancer endpoints has dropped a discussion on clinical trial designs that provide no treatment or use a placebo control